Background/Aims: We examined whether nicorandil, which is a hybrid of an adenosine triphosphate-sensitive potassium channel opener and a nitrate, could inhibit major adverse cardiac events (MACE) in maintenance hemodialysis patients with suspected myocardial ischemia. Methods: We enrolled 148 asymptomatic patients on maintenance hemodialysis, who had exhibited potential myocardial ischemia as assessed by myocardial fatty acid imaging. The end-point was MACE including cardiac death and non-fatal acute myocardial infarction. A propensity-matched analysis was performed. Results: Over a mean duration of follow-up of 2.8 ± 1.6 years in the 82 propensity-matched patients (41 in the nicorandil group and 41 in the non-nicorandil group), we observed 17 cardiac deaths and 12 cases of nonfatal myocardial infarction. The incidence of MACE was lower (p = 0.0365) in the nicorandil group (10/41, 24.4%) than in the non-nicorandil group (19/41, 46.3%). On stepwise Cox hazard analysis, MACE was significantly inhibited by administration of nicorandil (hazard risk, 0.387; 95% CI 0.178–0.842; p = 0.0168). Kaplan-Meier survival estimates revealed that MACE-free survival rates at 3 years were 80.5 and 58.5% in patients with and without nicorandil, respectively. Conclusions: Oral administration of nicorandil may offer new potential for the inhibition of MACE in hemodialysis patients.

Keywords:
Adenosine triphosphate, End-stage renal disease, Myocardial ischemia, Microcirculation, Potassium channel
1.
Taira N, Satoh K, Yanagisawa T, Imai Y, Hiwatari M: Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidoethyl nitrate (SG-75). Clin Exp Pharmacol Physiol 1979;6:301–316.
2.
Kukovetz WR, Holzmann S, Braida C, Pöch G: Dual mechanism of the relaxing effect of nicorandil by stimulation of cyclic GMP formation and by hyperpolarization. J Cardiovasc Pharmacol 1991;17:627–633.
3.
Taira N: Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989;63:18J–24J.
4.
Lee TM, Su SF, Chou TF, Lee YT, Tsai CH: Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation 2002;105:334–340.
5.
The IONA Study Group: Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomized trial. Lancet 2002;359:1269–1275.
6.
Ishii H, Toriyama T, Aoyama T, Takahashi H, Yamada S, Kasuga H, Ichimiya S, Kanashiro M, Mitsuhashi H, Maruyama S, Matsuo S, Naruse K, Matsubara T, Murohara T: Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. Clin Ther 2007;29:110–122.
7.
Kawai Y, Tsukamoto E, Nozaki Y, Morita K, Sakurai M, Tamaki N: Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol 2001;38:1888–1894.
8.
Yamabe H, Abe H, Yokoyama M, Shiotani H, Kajiya S, Mori T, Hashimoto Y: Resting 123I-BMIPP scintigraphy in diagnosis of effort angina pectoris with reference to subsets of the disease. Ann Nucl Med 1998;12:39–44.
9.
Tamaki N, Kawamoto M, Yonekura Y, Fujibayashi Y, Takahashi N, Konishi J, Nohara R, Kambara H, Kawai C, Ikekubo K, Kato H: Regional metabolic abnormality in relation to perfusion and wall motion in patients with myocardial infarction: assessment with emission tomography using an iodinated branched fatty acid analog. J Nucl Med 1992;33:659–667.
10.
Nishimura M, Hashimoto T, Kobayashi H, Fukuda T, Okino K, Yamamoto N, Fujita H, Inoue N, Nishimura T, Ono T: Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. Kidney Int 2004;66:811–819.
11.
Nishimura M, Murase M, Hashimoto T, Kobayashi H, Yamazaki S, Imai R, Okino K, Fujita H, Inoue N, Takahashi H, Ono T: Influence of diabetes mellitus on diagnostic potential of iodine-123-BMIPP imaging for coronary artery stenosis in hemodialysis patients. J Nephrol 2006;19:481–491.
12.
K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 2005;45:16–153.
13.
Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS: Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539–542.
14.
Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41–55.
15.
Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757–763.
16.
Joffe MM, Rosenbaum PR: Invited commentary: propensity scores. Am J Epidemiol 1999;150:327–333.
17.
D’Agostino PB Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265–2281.
18.
Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124–1136.
19.
Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, Sakai K, Ueda K: Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol 1997;30:970–975.
20.
Matsubara T, Minatoguchi S, Matsuo H, Hayakawa K, Segawa T, Matsuno Y, Watanabe S, Arai M, Uno Y, Kawasaki M, Noda T, Takemura G, Nishigaki K, Fujiwara H: Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol 2000;35:345–351.
21.
Kalliovalkama J, Jolma P, Tolvanen JP, Kähönen M, Hutri-Kähönen N, Saha H, Tuorila S, Moilanen E, Pörsti I: Potassium channel-mediated vasorelaxation is impaired in experimental renal failure. Am J Physiol 1999;277:H1622–H1629.
22.
Dikow R, Kihm LP, Zeier M, Kapitza J, Törnig J, Amann K, Tiefenbacher C, Ritz E: Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 2004;15:1530–1536.
23.
Tok D, Gullu H, Erdogan D, Topcu S, Ciftci O, Yildirim I, Muderrisoglu H: Impaired coronary flow reserve in hemodialysis patients: a transthoracic Doppler echocardiographic study. Nephron Clin Pract 2005;101:c200–c206.
24.
Akai K, Wang Y, Sato K, Sekiguchi N, Sugimura A, Kumagai T, Komaru T, Kanatsuka H, Shirato K: Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol 1995;26:541–547.
25.
Kasama S, Toyama T, Hatori T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M: Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. Am Heart J 2005;150:477.
26.
Winkelmayer WC, Owen WF Jr, Levin R, Avorn J: A propensity analysis of late versus early nephrologists referral and mortality on dialysis. J Am Soc Nephrol 2003;14:486–492.
27.
Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG: Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 2004;15:477–486.
28.
Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA: Survival after coronary revascularization among patients with kidney disease. Circulation 2004;110:1890–1895.
29.
Herzog CA, Li S, Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT: Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005;68:818–825.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.